MiNK Therapeutics & Neurocrine Biosciences
3 shared events · Importance 3 · Last updated Apr 15, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
MiNK Therapeutics: MiNK Therapeutics is being acquired by Neurocrine Biosciences for $2.9 billion, representing a significant premium for its shareholders. Its product, VYKAT XR, is a key asset in this transaction.
Neurocrine Biosciences: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio in endocrinology and rare diseases with the addition of VYKAT XR. This acquisition is expected to accelerate revenue growth and diversify its product offerings.
Apr 06, 2026 · 6 articles
Business
Neurocrine Biosciences: Neurocrine Biosciences is acquiring MiNK Therapeutics for $2.9 billion, expanding its portfolio into metabolic disorders with the addition of VYKAT XR. This deal is seen as a strategic entry into the metabolic disease market.
Apr 06, 2026 · 6 articles
Business
Neurocrine Biosciences: Neurocrine Biosciences, Inc. is the proposed acquirer of MiNK Therapeutics.
Apr 01, 2026 · 47 articles
NEWSDESK
Explore this relationship live
Track how MiNK Therapeutics and Neurocrine Biosciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard